Impact of urinary albumin excretion on the onset of adverse reactions to vancomycin hydrochloride. 2021

Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka

OBJECTIVE Vancomycin dose needs to be reduced for decreased kidney function; however, impact of urinary albumin excretion (UAE) on serum vancomycin level is unknown. In this study, we examined the factors associated with the onset of renal impairment induced by vancomycin by focusing on UAE. METHODS The study included 52 patients who received vancomycin for methicillin-resistant Staphylococcus aureus at Ehime University Hospital between April 2010 and March 2015. To determine the presence of renal impairment, patients whose common terminology criteria for adverse-events (CTCAE) grade worsened by 1 or more comprised the renal impairment group, and multivariate logistic regression analysis was performed. RESULTS 13 patients (25%) had renal impairment as indicated by a CTCAE grade change by 1 or more. The results of multivariate logistic regression analysis only of UAE (OR = 18.03; 95% CI = 1.97 - 164.89) was identified as a significant factor. CONCLUSIONS We investigated the factors associated with the onset of renal impairment induced by vancomycin and identified UAE as a potential risk factor.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000418 Albumins Water-soluble proteins found in egg whites, blood, lymph, and other tissues and fluids. They coagulate upon heating. Albumin
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013203 Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS. Infections, Staphylococcal,Staphylococcus aureus Infection,Staphylococcal Infection,Staphylococcus aureus Infections
D014640 Vancomycin Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. AB-Vancomycin,Diatracin,VANCO-cell,Vanco Azupharma,Vanco-saar,Vancocin,Vancocin HCl,Vancocine,Vancomicina Abbott,Vancomicina Chiesi,Vancomicina Combino Phar,Vancomicina Norman,Vancomycin Hexal,Vancomycin Hydrochloride,Vancomycin Lilly,Vancomycin Phosphate (1:2),Vancomycin Phosphate (1:2), Decahydrate,Vancomycin Sulfate,Vancomycin-ratiopharm,Vancomycine Dakota,Hydrochloride, Vancomycin,Sulfate, Vancomycin
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus

Related Publications

Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
April 2020, BMC nephrology,
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
August 1985, Lancet (London, England),
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
January 1993, The Annals of pharmacotherapy,
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
August 1993, Critical care medicine,
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
December 2017, Journal of children's orthopaedics,
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
December 1991, Journal of cardiothoracic and vascular anesthesia,
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
January 2002, British journal of clinical pharmacology,
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
February 2007, British journal of clinical pharmacology,
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
January 1991, Acta diabetologica latina,
Hiroshi Kimura, and Akihiro Tanaka, and Shinichi Watanabe, and Noriaki Hidaka, and Mamoru Tanaka
February 1986, British journal of obstetrics and gynaecology,
Copied contents to your clipboard!